Improvement in Cardiometabolic Risk Factors During Smoking Cessation Treatment in Patients with Type 2 Diabetes: A Retrospective Cohort Study.

PURPOSE: Smoking cessation reduces morbidity and mortality of cardiovascular diseases. The purpose of this study was to evaluate the effect during smoking cessation treatment on glycemic control and cardiometabolic risk factors, including blood pressure and lipid levels, in patients with type 2 diabetes. PATIENTS AND METHODS: This retrospective cohort study included patients with type 2 diabetes who participated in a smoking cessation program, which comprised health education and medication prescription at an outpatient clinic in combination with a 3-month follow-up by phone. Data on patient background characteristics, cardiometabolic factors, smoking status, body weight, and body mass index before and after the program were collected for analysis.
RESULTS: The analysis included 241 participants with an average age of 58.6 ± 10.6 years. The rate of successful cessation at three months was 34.0%. Compared with the baseline levels, there were significant decreases in the levels of fasting plasma glucose (10.0 ± 46.8 mg/dL, P = 0.001), HbA1c (0.3 ± 1.4%, P = 0.004), systolic blood pressure (4.6 ± 17.5 mmHg, P < 0.001), diastolic blood pressure (2.9 ± 11.3 mmHg, P < 0.001), and total cholesterol (7.9 ± 42.8 mg/dL, P = 0.020) after participation in the smoking cessation program while there was no significant difference in body weight (0.1 ± 1.2 kg, P = 0.444). After adjustment for covariates, the decreases in HbA1c and total cholesterol levels were significantly better in younger participants and higher baseline nicotine dependence scores were associated with decreases in the levels of blood pressure, fasting plasma glucose, and triglycerides. However, the decrease in smoking amount was not associated with the changes in cardiometabolic factors.
CONCLUSION: Participation in a smoking cessation program was associated with improvements in glycemic control and cardiometabolic risk factors in patients with type 2 diabetes. The observed improvements were associated with participation in the program but not with the decrease in smoking amount.

Introduction

The prevalence of type 2 diabetes is approximately 8.8% globally and 10.1% in Taiwan,1,2 and both numbers continue to increase.3,4 Cardiovascular diseases (CVDs) are the leading cause of mortality in patients with type 2 diabetes, with an estimated rate of nearly 52%.5 Importantly, cigarette smoking is associated with metabolic syndrome, intrahepatic fat,6 and CVDs.7 The prevalence of tobacco smoking, which is around 24.9% in the general population,8 is even higher in patients with type 2 diabetes, reaching up to 32.1% to 33.9%.9,10 Studies had established that smoking is associated with higher rates of overall mortality as well as higher rates of CVD risk and mortality among patients with diabetes.11,12 Several studies have also demonstrated that smoking patients with type 2 diabetes patients have worse disease control and more severe complications such as diabetic foot ulcers.13–16

On the other hand, smoking cessation has been shown to reduce cardiometabolic risk and improve glycemic control.17,18 One study showed that the hazard ratio of cardiovascular mortality compared to never smokers was 2.07 (95% CI 1.82 to 2.36) for current smokers and 1.37 (1.25 to 1.49) for former smokers, respectively.17 The other study revealed that HbA1c decreased linearly with an increase in years after smoking cessation in former smokers (P <0.001).18 However, there were few studies analyzing the factors influencing these effect of the smoking cessation. Besides, few studies analyzed the short-term effects on blood pressure, lipid profiles, and glycemic control during smoking cessation program.

The aim of the present study was to evaluate the effects during a smoking cessation program on glycemic control and cardiometabolic risk factors including systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose, hemoglobin A1c (HbA1c), total cholesterol (TC), and triglycerides in patients with type 2 diabetes and to analyze the factors influencing the effect.

Patients and Methods

Design, Setting and Recruitment

This is a hospital-based, retrospective, cohort study. We included patients with type 2 diabetes who underwent Taiwan’s second-generation smoking cessation program between January 2017 and March 2019 at the outpatient clinics in Mackay Memorial Hospital, Taipei, Taiwan. All participants attended the program were over 18 years old either with a daily smoking amount more than 10 cigarettes and/or with an Fagerström test for nicotine dependence (FTND) score of at least 4 points (scores range from 0 to 10, with higher scores representing greater nicotine dependence). The diagnosis of type 2 diabetes was based on the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) code E11.0–11.9 in medical records or the laboratory data indicating a fasting glucose level of >126 mg/dL or a hemoglobin A1c (HbA1c) level >6.5% at first personal consultation for smoking cessation.

A total of 458 patients with results of blood tests in the smoking cessation program were included. 141 patients with missing data of fasting glucose or HbA1C before and after the program period were excluded in this study. We also excluded 42 patients lacking abstinence status and 34 patients with incorrectly recorded smoking years or daily amount. Eventually, 241 diabetes patients were enrolled in the study (Figure 1).

Figure 1

Flow chart of the selection of study patients.

Measurement and Methods

The smoking cessation program included health education and medical prescription by the physician at the outpatient clinic in combination with a 3-month follow-up by phone by the health promotion agency.

In the clinic, the patients received counseling from the physician. Smoking habits including daily consumption of cigarette, smoking year, and smoking pack-year were obtained and the FTND score was assessed at the first clinic visit. The possible side effects and contraindication of respective medication, withdrawal symptoms of smoking cessation, and the benefits from smoking cessation were informed and discussed. Varenicline and/or nicotine replacement therapy was prescribed based on shared decision-making during a maximum 8-week course divided into several clinic visits. The smoking status, adverse effects of medication, and exhaled carbon monoxide levels (ppm) were evaluated at each clinic visit.

The health promotion agency interviewed the patients in the clinic or by telephone. The assistance was provided including listening to the current experience of smoking cessation, understanding the obstacles, reinforcing the will and motivation, and the management of expected withdrawal symptoms and side effects of medication. The self-reported smoking status by telephone after the program was used to determine the success of smoking cessation at the 3rd month. If we could not contact the patient by phone, the individual would be categorized into failure in smoking cessation at the 3rd month.

We reviewed the patients’ medical records. The clinical characteristics of all participants, including sex, age, smoking years, smoking amount, FTND score, and baseline exhaled carbon monoxide, were recorded. The participants were defined to have previous diagnosis of hypertension and CVD if they had the diagnoses in their medical records. Additionally, data on the following parameters were obtained from the electronic medical record system: SBP, DBP, fasting plasma glucose, HbA1c, TC, triglycerides, smoking amount, body weight, body height, and body mass index (BMI) before and after the smoking cessation program. Using varenicline or not during the smoking cessation program was also recorded.

Ethics Statement

The present study was authorized by the Ethics Committee of Mackay Memorial Hospital (Institutional review board number: 17MMHIS049) based on the revised Helsinki Declaration. This study is a non-interventional, observational, and retrospective study with minimal risk for the participants, and the informed consent from the participants was not deemed necessary. The data were collected, analyzed, and used only for research purposes. The study was carried out in accordance with the local regulatory guidelines and international guidelines for good epidemiological practices.

Statistical Analysis

All statistical analyses were performed using SPSS software (version 22.0, SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as means ± standard deviation, and categorical variables were expressed as numbers with percentages. Paired t test was used to compare daily smoking amount (stick/day), glycemic control, cardiometabolic risk factors, body weight, and BMI before and after the smoking cessation program. Logistic regression was used to determine factors associated with improvements in cardiometabolic factors. Multiple logistic regression analysis with covariates of age, sex, daily smoking amount, duration of smoking, and FTND score was performed to compare patients categorized into those with and without decreases in the levels for SBP, DBP, fasting glucose, HbA1c, TC, and triglycerides after the cessation program.

Results

The retrospective study cohort finally enrolled a total of 241 patients. The characteristics of the enrolled patients are summarized in Table 1. The cohort comprised 34 (14.1%) female patients, and the average age was 58.6 ± 10.6 years. The average body height was 165.2 ± 6.8 cm, the average body weight was 73.7 ± 13.8 kg, and the average BMI was 26.9 ± 4.7 kg/m2. There were 165 (68.5%) and 83 (34.4%) patients with previous diagnoses of hypertension and CVD, respectively. The average baseline FTND score, smoking duration, baseline carbon monoxide level, and baseline smoking amount were 6.3 ± 2.4 points, 35.4 ± 11.8 years, 18.0 ± 3.5 ppm, and 21.4 ± 12.9 sticks/day, respectively. After the smoking cessation program, the average smoking amount was 12.8 ± 12.7 sticks/day. There were 186 (77.2%) patients who ever used varenicline in the cessation program. The successful cessation number was 82 (34.0%) at the 3-month follow-up by phone.

Table 1

Characteristics of the Study Participants

	Total (n = 241)
Variable	Mean ± SD or n (%)
Sex (female, n, %)	34 (14.1)
Age (years)	58.6 ± 10.6
Body height (cm)	165.2 ± 6.8
Body weight (kg)	73.7 ± 13.8
BMI (kg/m2)	26.9 ± 4.7
Hypertension (n, %)	165 (68.5)
CVD (n, %)	83 (34.4)
Baseline FTND score (points)	6.3 ± 2.4
Smoking year (years)	35.4 ± 11.8
Baseline exhaled CO (ppm)	18.0 ± 3.5
Baseline smoking amount (sticks/day)	21.4 ± 12.9
Smoking amount after the program (sticks/day)	12.8 ± 12.7
Successful cessation rate at three months (n, %)	82 (34.0)
Ever using varenicline (n, %)	186 (77.2)

Abbreviations: BMI, body mass index; CO, carbon monoxide; CVD, cardiovascular disease; FTND score, Fagerström test for nicotine dependence score; SD, standard deviation.

The comparisons of cardiometabolic factors before and after participation in the smoking cessation program are summarized in Table 2. The smoking amount was decreased by 8.7 ± 12.3 sticks/day after the smoking cessation program (P < 0.001). The decreases in the levels of SBP, DBP, fasting glucose, HbA1c, TC, and triglycerides were found in 91 (37.8%), 92 (38.2%), 135 (56.0%), 107 (44.4%), 86 (52.4%), and 90 (71.8%) patients, respectively. Compared with the baseline values, the decreases after participation in the smoking cessation program were significant for the levels of fasting glucose (10.0 ± 46.8 mg/dL, P = 0.001), HbA1c (0.27% ± 1.4%, P = 0.004), SBP (4.6 ± 17.5 mmHg, P < 0.001), DBP (2.9 ± 11.3 mmHg, P < 0.001), and TC (7.9 ± 42.8 mg/dL, P = 0.02). However, the triglyceride levels did not show a significant change after participation in the smoking cessation program (26.7 ± 198.1 mg/dL, P = 0.078). Additionally, there was no significant difference in body weight (0.1 ± 1.2 kg, P = 0.444) or BMI (0.01 ± 0.47 kg/m2, P = 0.737) with participation in the smoking cessation program.

Table 2

Comparison of Changes in Cardiometabolic Factors After Participation in the Smoking Cessation Program

Variable	Patients with Reduced Value (n, %)	Before Participation	After Participation	Difference	P value*
	Mean ± SD or N (%)
Smoking amount (stick/day)	123 (51.0)	21.4 ± 12.9	12.8 ± 12.7	8.7 ± 12.3	<0.001
SBP (mmHg)	91 (37.8)	134.2 ± 19.1	129.6 ± 14.4	4.6 ± 17.5	<0.001
DBP (mmHg)	92 (38.2)	79.5 ± 12.5	76.6 ± 10.1	2.9 ± 11.3	<0.001
Fasting glucose (mg/dL)	135 (56.0)	142.6 ± 43.6	132.6 ± 33.7	10.0 ± 46.8	0.001
HbA1c (%)	107 (44.4)	7.3 ± 1.5	7.0 ± 1.0	0.27 ± 1.4	0.004
TC (mg/dL)	86 (52.4)	179.9 ± 46.5	172.1 ± 38.1	7.9 ± 42.8	0.02
TG (mg/dL)	90 (71.8)	217.6 ± 203.9	190.9 ± 126.1	26.7 ± 198.1	0.078
Body weight (kg)	52 (22.3)	73.7 ± 13.8	73.7 ± 13.9	0.1 ± 1.2	0.444
BMI (kg/m2)	52 (22.3)	26.9 ± 4.7	26.8 ± 4.7	0.01 ± 0.47	0.737

Note: *Paired t test.

Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.

The analysis of factors associated with improvements in cardiometabolic factors is summarized in Table 3. In multiple logistic regression models, patient age was associated with decreases in HbA1c (odds ratio [OR] 0.95, 95% confidence interval [CI] 0.92–0.99) and TC (OR 0.95, 95% CI 0.92–0.99) levels, baseline smoking amount was associated with a decrease in DBP (OR 0.96, 95% CI 0.93–0.98), and baseline FTND score was associated with decreases in fasting glucose (OR 1.15, 95% CI 1.01–1.31), SBP (OR 1.22, 95% CI 1.06–1.40), DBP (OR 1.15, 95% CI 1.00–1.31), and triglyceride (OR 1.16, 95% CI 1.00–1.315) levels. However, baseline smoking duration and the decrease in smoking amount did not show significant associations with improvement in any of the cardiometabolic factors included in the analyses.

Table 3

Factors Associated with Improvements in Cardiometabolic Factors During Smoking Cessation Treatment in Patients with Type 2 Diabetes

Variable	Decreased HbA1c	Decreased Fasting Glucose	Decreased SBP	Decreased DBP	Decreased TC	Decreased TG
	Odds Ratio (95% Confidence Interval)*
Sex (male)	1.30 (0.59–2.86)	1.43 (0.66–3.09)	0.95 (0.44–2.06)	2.09 (0.89–4.92)	0.92 (0.37–2.29)	1.13 (0.49–2.61)
Age	0.95 (0.92–0.99)	1.02 (0.98–1.05)	0.99 (0.95–1.02)	0.99 (0.96–1.03)	0.95 (0.92–0.99)	0.97 (0.93–1.01)
Baseline smoking year	1.01 (0.98–1.05)	0.98 (0.95–1.01)	0.99 (0.96–1.03)	1.00 (0.97–1.04)	0.99 (0.96–1.03)	1.00 (0.97–1.04)
Baseline smoking amount	1.00 (0.97–1.03)	1.00 (0.98–1.03)	0.98 (0.95–1.01)	0.96 (0.93–0.98)	0.97 (0.94–1.01)	0.98 (0.96–1.01)
Baseline FTND score	0.92 (0.80–1.04)	1.15 (1.01–1.31)	1.22 (1.06–1.40)	1.15 (1.00–1.31)	1.17 (0.99–1.37)	1.16 (1.00–1.35)
Decreased smoking amount	0.98 (0.96–1.01)	0.98 (0.96–1.01)	1.00 (0.97–1.02)	1.01 (0.99–1.04)	1.00 (0.97–1.03)	1.01 (0.98–1.04)

Note: *Multiple logistic regression.

Abbreviations: DBP, diastolic blood pressure; FTND score, Fagerström test for nicotine dependence score; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.

Discussion

The present study was designed to evaluate the effect during a smoking cessation program on glycemic control and cardiometabolic risk factors in patients with type 2 diabetes and to determine factors associated with the observed effect. Our analyses revealed that improvements in glycemic control and cardiometabolic risk factors were noted by three months after participation in the smoking cessation program. The effect was more predominant in patients who were younger and in those with lower baseline smoking amount and higher baseline FTND scores. Our analyses also demonstrated that the decrease in smoking amount was not associated with the observed improvements in glycemic control and cardiometabolic factors. These findings are consistent with those of a previous study showing that smoking cessation intervention was associated with lower mortality compared with usual care, although successful smoking cessation was achieved in a minority of participants.19

The positive cardiometabolic effects of smoking cessation observed in our study was reported by several other studies, indicating that smoking cessation improves glycemic control and is associated with cardiovascular benefit.18,20 Additionally, one study showed that smoking cessation improved both mental and physical health-related quality of life among patients with type 2 diabetes.21 However, several studies reported that smoking cessation might deteriorate glycemic control and cardiometabolic factors and that these changes were primarily secondary to weight gain.22–25 One study also demonstrated that smoking cessation without instruction might contribute to the development of metabolic syndrome.26 In the present study, participants did not experience a significant body weight change after the smoking cessation program and the effects of participation in the program on glycemic control and cardiometabolic factors were in contrast to the findings of the abovementioned studies. These results suggest that adequate weight control during smoking cessation might contribute to improvements in glycemic control and cardiometabolic factors.

Studies revealed that behavioral modification improved glycemic control in patients with type 2 diabetes.27,28 Motivational interviewing is especially favorable for weight management in type 2 diabetes.27 The smoking cessation program in our study provided health education to help patients control weight. One study showed that behavior change techniques achieved significant reductions in HbA1c at three and six months,28 which was compatible with the duration of the smoking cessation program in our study. Thus, we hypothesize that observed improvements in glycemic control and cardiometabolic factors in patients with type 2 diabetes after their participation in the smoking cessation program might be due to the modification of views and behaviors in association with the health education and enhanced adherence during the program and not due to a decrease in smoking amount.

As above-mentioned, studies had established the long-term effects of successful smoking cessation on cardiometabolic factors. Some studies also revealed that the reduction of vascular inflammation was noted during smoking cessation in less than 6 months.29,30 However, few studies focused on the short-term effects on the blood pressure, lipid profiles, and glycemic control during smoking cessation. The present study revealed that the immediate improvement of cardiometabolic factors among diabetes patients during the smoking cessation program can be seen in three months.

Since participation in a smoking cessation program is associated with improvements in glycemic control and cardiometabolic factors and as the effect could be observed in three months, we strongly suggest that clinicians in general practice should recommend patients with type 2 diabetes to participate in a smoking cessation program.

The present study has several limitations. First, since information was retrieved from medical records, we could not include information on waist circumference, changes in diet, and changes in physical activities, which are significant factors contributing to improvements in cardiometabolic factors. Second, we enrolled patients with newly diagnosed type 2 diabetes as well as those stable patients under diabetes treatment for longer time periods. It remains possible that patients with a new diagnosis might have affected the average blood glucose levels of the study cohort. However, our statistical analyses after the exclusion of 12 patients with newly diagnosed type 2 diabetes yielded comparable results. Third, the study sample size was relatively small and limited to one medical hospital. The study participants were also followed for approximately three months during the smoking cessation program, and the long-term effects require further validation. However, despite these limitations, the study findings reflect the real-world situation and highlight the need for further investigation into the impact of smoking cessation programs on cardiometabolic factors in patients with type 2 diabetes.

Conclusion

Participation in a smoking cessation program was associated with improvements in glycemic control and cardiometabolic risk factors in patients with type 2 diabetes in 3 months. Moreover, younger patients exhibited better improvement in HbA1c and TC than older patients, whereas patients with a lower baseline smoking amount experienced better improvement in DBP. The Improvements in fasting glucose, SBP, DBP, and triglycerides were better in patients with higher baseline FTND scores as well. However, these observed improvements in cardiometabolic factors were associated with participation in the program but not with the decrease in smoking amount.